EIKEN嗜肺军团菌快速检测卡

广州健仑生物科技有限公司

主要用途：用于检测尿样中嗜肺军团菌血清型1抗原，以支持军团菌感染的诊断。

产品规格：20T/盒

存储条件：2-30℃

EIKEN嗜肺军团菌快速检测卡

我司还提供其它进口或国产试剂盒：登革热、疟疾、西尼罗河、立克次体、无形体、蜱虫、恙虫、利什曼原虫、RK39、汉坦病毒、深林脑炎、流感、A链球菌、合胞病毒、腮病毒、乙脑、寨卡、黄热病、基孔肯雅热、克锥虫病、违禁品滥用、肺炎球菌、军团菌、化妆品检测、食品安全检测等试剂盒以及日本生研细菌分型诊断血清、德国SiFin诊断血清、丹麦SSI诊断血清等产品。

欢迎咨询

欢迎咨询2042552662

【产品介绍】

EIKEN

二维码扫一扫

【公司名称】 广州健仑生物科技有限公司
【】    杨永汉 
【】 
【腾讯 】 2042552662
【公司地址】 广州清华科技园创新基地番禺石楼镇创启路63号二期2幢101-3室
【企业文化】

大脑细胞的自我更新能力很差，细胞疗法可使丢失脑细胞的得以更新，已成为中枢神经系统损伤治疗的潜力性方法。骨髓间充质干细胞因其可分化为神经元/神经细胞，又可通过血脑屏障迁移至损伤神经组织，还能分泌神经营养因子，营造利于神经再生的微环境，也被认为是有希望的细胞治疗项目。
伊朗Shahid Sadoughi 大学医学院的Mohammad Ali Khalili教授所在研究团队，设计了给创伤性脑损伤模型大鼠尾静脉注射3×106大鼠骨髓间充质干细胞，静脉移植后显著促进了创伤性损伤大脑皮质神经细胞的再生，作者认为此方法可成为因损伤而丢失神经细胞的有益补充。相关研究成果发表在《中国神经再生研究(英文版)》杂志2014年5月第9期。
在人类细胞中，位于制造能量的称为线粒体的结构中的DNA 可能出现突变从而形成多个DNA变种。这种称为异质性的情况是一批疾病的原因，但是健康人群的线粒体基因组中的致病异质性的流行程度尚不清楚，这部分是由于样本数量少或者此前研究的不充分的测序方法。
Zhenglong Gu及其同事分析了1000基因组项目的14个人群的1085个健康个体的整个线粒体基因组高质量下一代测序数据。这些人的90%拥有至少一种异质性，但是多数人的异质性数量低。然而，所有这些人的19%携带了至少一种与疾病有关的异质性。
这组作者说，随着时间的推移，健康个体的可能有害的线粒体DNA变种的数量可能在一些细胞中增加，zui终达到了一个可能致病的临界极限值，这强调了管理异质性从而防止疾病进程的重要性。
美国Salk研究所Juan Carlos Izpisua Belmonte实验室、华大基因(BGI)李英睿团队和中科院生物物理研究所刘光慧研究组合作，*利用全基因组测序(WGS)明确了现有疾病基因组靶向矫正工具的安全可靠性，并创建了效率远高于目前基因组靶向编辑技术的新型人类遗传突变修复工具HDAdV，为开展以干细胞为基础的基因治疗提供了重要的理论依据。 相关文章发表于2014年7月3日的《Cell Stem Cell》杂志上。
例子：血红蛋白疾病(如镰刀形细胞贫血症和地中海贫血症)的再生医学治疗策略
人诱导多能干细胞技术(iPSC)的出现，促进了人类疾病基因组靶向矫正技术的快速发展。目前可用于人类疾病基因组靶向矫正的方法包括：核酶介导的DNA同源重组技术(如ZFN，TALEN及CRISPR/CAS9等)以及不依赖于核酶的大片段DNA同源重组技术(以第三代腺病毒载体HDAdV为代表)。经遗传修复的自体干细胞具有治疗自身疾病的潜力，因此在个体医学和再生医学中具有广阔的应用前景。
刘光慧研究团队曾zui早利用HDAdV介导的基因组靶向编辑技术在儿童早衰症患者iPSC中实现了对致病基因LMNA的靶向修复，从概念上证实了在病人细胞中原位矫正遗传突变的可行性。他们继而矫正了帕金森氏症和范可尼贫血症患者干细胞中的致病突变，为这些遗传疾病的机理研究、药物评价及个性化干细胞和基因治疗奠定了基础。

Brain cells are poor at self-renewal and cell therapies that allow for the loss of brain cells have been renewed and have become a potential method of treatment for CNS injury. Bone marrow-derived mesenchymal stem cells are also considered promising because of their ability to differentiate into neurons / neurons, migration to damaged nerve tissue through the blood-brain barrier, secretion of neurotrophic factors, and creation of a microenvironment conducive to nerve regeneration Cell Therapy Project.
Professor Mohammad Ali Khalili, a professor at the Shahid Sadoughi University School of Medicine in Iran, designed a rat model of traumatic brain injury to inject 3 × 10 6 rat bone marrow mesenchymal stem cells into the tail vein of the traumatic brain injury model and significantly promote traumatic injury to the cerebral cortex Regeneration of nerve cells, the authors believe that this method can become a beneficial supplement due to injury and loss of nerve cells. Relevant research results published in the "Chinese Journal of Nervous Regeneration Research (English Edition)" magazine in May 2014 No. 9.
In human cells, DNA located in the structure called mitochondria that make energy can mutate to form multiple DNA variants. This condition, known as heterogeneity, is responsible for a number of diseases, but the prevalence of pathogenic heterogeneity in the mitochondrial genome of healthy populations is unclear, partly due to the small sample size or inadequay studied Sequencing method.
Zhenglong Gu and colleagues analyzed high-quality, next-generation sequencing data from the entire mitochondrial genome of 1085 healthy individuals in 14 global populations of 1000 genome projects. 90% of these people have at least one heterogeneity, but most people have low levels of heterogeneity. However, 19% of all these people carry at least one disease-related heterogeneity.
Over time, the authors say, the number of potentially harmful mitochondrial DNA variants in healthy individuals may increase in some cells, culminating in a potentially pathogenic threshold, emphasizing the management of heterogeneity and thus preventing The importance of the disease process.
The team of Juan Carlos Izpisua Belmonte, Salk Institute of USA, BGL Li Ying-Rui team and Liu Guang-hui Research Group, Institute of Biophysics, Chinese Academy of Sciences, for the first time made use of whole genome sequencing (WGS) to clarify the safety of existing disease genomic targeted remediation tools Reliability and create HDAdV, a novel human genetic mutation repair tool far more efficient than current genomic targeted editing techniques, providing an important theoretical basis for stem cell-based gene therapy. The article appeared in the July 3, 2014 issue of Cell Stem Cell.
Examples: Regenerative medical treatment strategies for hemoglobin diseases such as sickle cell anemia and thalassemia
The advent of human induced pluripotent stem cell technology (iPSC) has led to the rapid development of targeted therapies for human disease genomes. Currently available methods for target-directed genomic remediation of human diseases include ribozyme-mediated DNA homologous recombination techniques (eg, ZFN, TALEN and CRISPR / CAS9, etc.) and large fragment DNA-independent recombination techniques independent of ribozyme Third generation adenovirus vector HDAdV is representative). Genetically repaired autologous stem cells have the potential to treat their own diseases and therefore have broad applications in both individual medicine and regenerative medicine.
Liu Guanghui's team first used the HDAdV-mediated genome-targeted editing technique to target the pathogenic gene LMNA in the iPSC of patients with APA, and conceptually confirmed the feasibility of in situ correction of genetic mutations in patient cells . They then corrected pathogenic mutations in stem cells in patients with Parkinson's and Fanconi anemia and laid the foundation for mechanistic studies of these genetic diseases, drug evaluation, and personalized stem cell and gene therapy.